Kurt Hertogs

Kurt Hertogs publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Kurt Hertogs sits on this spectrum.

Kurt Hertogs D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Kurt Hertogs sits on this spectrum.

Overview

Best Publications

• A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

  Kurt Hertogs;Marie-Pierre de Béthune;Veronica Miller;Tania Ivens

  667
  Citations

• Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

  Lee Bacheler;Susan Jeffrey;George Hanna;Richard D'Aquila

  326
  Citations

• Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

  Veronica Miller;Caroline Sabin;Kurt Hertogs;Stuart Bloor

  287
  Citations

• Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

  K. Hertogs;S. Bloor;S. D. Kemp;C. van den Eynde

  259
  Citations

• A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

  Calvin J. Cohen;Susan Hunt;Michael Sension;Charles Farthing

  247
  Citations

• Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

  Inge Dierynck;Mieke De Wit;Emmanuel Gustin;Inge Keuleers

  213
  Citations

• A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

  B. A. Larder;S. Bloor;S. D. Kemp;Kurt Hertogs

  210
  Citations

• Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

  Brendan A. Larder;Kurt Hertogs;Stuart Bloor;Ch. Van Den Eynde

  209
  Citations

• Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters

  Mark Dybul;Tae-Wook Chun;Christian Yoder;Bertha Hidalgo

  193
  Citations

• Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

  Olivia Goethals;Reginald Clayton;Marcia Van Ginderen;Inge Vereycken

  192
  Citations

• Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

  P. Harrigan;Kurt Hertogs;Werner Verbiest;Rudi Pauwels

  164
  Citations

• Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.

  Jerome Guillemont;Elisabeth Pasquier;Patrice Palandjian;Daniel Vernier

  163
  Citations

• Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

  Miller;Anne-Mieke Vandamme;C Loveday;S Staszewski

  151
  Citations

• High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

  Christiane Adjé;Rachanee Cheingsong;Thierry H. Roels;Chantal Maurice

  145
  Citations

• Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

  Scott A. Wegner;Stephanie K. Brodine;John R. Mascola;Sybil A. Tasker

  145
  Citations

• A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V

  K Hertogs;S Bloor;V De Vroey;C van Den Eynde

  140
  Citations

• The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis.

  P Hilton;K Hertogs;S L Stanton

  133
  Citations

• Endonexin II, Present on Human Liver Plasma Membranes, Is a Specific Binding Protein of Small Hepatitis B Virus (HBV) Envelope Protein

  Kurt Hertogs;William P.J. Leenders;Erick Depla;Wieke C.C. De Bruin

  129
  Citations

• Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.

  Christian Eggers;Kurt Hertogs;Hans-Jörg Stürenburg;Jan van Lunzen

  126
  Citations

• Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

  Michael D. Miller;Nicolas A. Margot;Kurt Hertogs;Brendan Larder

  118
  Citations

• Long-Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters

  Mark Dybul;Elizabeth Nies-Kraske;Marybeth Daucher;Kurt Hertogs

  115
  Citations